CAR T manufacturers and payers are still negotiating access for B cell lymphoma patients without other treatment options, but that hasn’t stopped companies from pressing on into earlier lines of treatment....

Taysha raises $157M in IPOShares of Taysha Gene Therapies Inc. (NASDAQ:TSHA) rose $4.06 (20%) to $24.06 in the CNS disorders company’s first day of trading, after it raised $157 million in an upsized IPO through the sale...

With a platform to perform in vivo brain imaging, Inscopix Inc. is aiming to fix the poor predictive power of preclinical animal models for CNS diseases. Its advantage is the ability to use changes in...

INDICATION: Hearing loss Mouse studies suggest CLRN1 gene therapy could help treat hearing loss in Usher syndrome type 3A, which is caused by CLRN1 mutations. In a hair cell-specific CLRN1 knockout mouse model of Usher...

Gilead Sciences Inc. (NASDAQ:GILD) added a late-stage cancer asset and pivoted toward the chimeric antigen receptor (CAR) T cell therapy space after agreeing to acquire Kite Pharma Inc. (NASDAQ:KITE) at $180 per share in cash,...

Gilead Sciences Inc. (NASDAQ:GILD) added a late-stage cancer asset and pivoted toward the chimeric antigen receptor (CAR) T cell therapy space after agreeing to acquire Kite Pharma Inc. (NASDAQ:KITE) at $180 per share in cash,...

In a paper published in The Journal of Neuroscience , scientists showed that reduction of solute carrier family 6 member 15 (SLC6A15) , a neutral amino acid transporter, in the nucleus accumbens is linked to increased susceptibility...

Exosomes are emerging as one of the newest technologies for creating diagnostics and delivering therapeutics, primarily in cancer. Evox Therapeutics Ltd. is joining the growing list of start-ups, using science from exosome pioneer Matthew Wood...

Spanish venture firm Ysios Capital Partners closed its second fund, Ysios BioFund II Innvierte, with EUR 126.4 million ($138.7 million). The raise was above its EUR 100 million ($109.8 million) target (see BioCentury Extra, March...